US equities
|
NVDA
$237.20
▲+1.39%
SPCX
$165.31
▲+4.00%
MU
$1,059.24
▼-1.46%
TSLA
$375.93
▲+1.44%
MSFT
$527.84
▲+1.99%
INTC
$115.97
▼-2.82%
SNDK
$1,718.09
▼-0.11%
AMD
$627.51
▼-1.01%
NVDA
$237.20
▲+1.39%
SPCX
$165.31
▲+4.00%
MU
$1,059.24
▼-1.46%
TSLA
$375.93
▲+1.44%
MSFT
$527.84
▲+1.99%
INTC
$115.97
▼-2.82%
SNDK
$1,718.09
▼-0.11%
AMD
$627.51
▼-1.01%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Lexaria Bioscience Corp. - Common Stock
(NQ:
LEXX
)
3.000
+0.120 (+4.17%)
Delayed Quote
Updated: 10:00 AM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lexaria Bioscience Corp. - Common Stock
< Previous
1
2
...
21
22
23
24
25
26
27
28
29
...
32
33
Next >
Lexaria’s (NASDAQ: LEXX) IP Portfolio Grows Following Receipt of 24th Granted Patent
March 22, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Lexaria Bioscience Commences DehydraTECH-CBD Epilepsy Research Program
↗
March 16, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Commences DehydraTECH-CBD Epilepsy Research Program
March 16, 2022
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Commencement of DehydraTECH-CBD Epilepsy Research Program
March 15, 2022
Via
Investor Brand Network
Lexaria Begins DehydraTECH-CBD Epilepsy Research Program
March 15, 2022
- Program EPIL-A21-1 will compare effectiveness of FDA-approved Epidiolex to DehydraTECHTM-CBD for reducing seizure activity; - DehydraTECH-CBD test articles have been delivered to the laboratory ready...
From
Lexaria Bioscience Corp.
Via
AccessWire
Lexaria Bioscience Receives Award For Oral Nicotine Compound Patent
↗
March 09, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience (NASDAQ: LEXX), a...
Via
Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Receives Award for Oral Nicotine Compound Patent
March 09, 2022
Via
Investor Brand Network
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Award for Oral Nicotine Compound Patent
March 08, 2022
Via
Investor Brand Network
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Award for Oral Nicotine Compound Patent
March 08, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
Lexaria Granted Important New Oral Nicotine Patent
March 08, 2022
Newest granted patent expands worldwide patent portfolio to 24 KELOWNA, BC / ACCESSWIRE / March 8, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Studies Advance Lexaria Bioscience's Tech For Improving Pharmaceutical Drugs
↗
March 07, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience is dedicated to...
Via
Benzinga
Studies Advance Lexaria Bioscience’s (NASDAQ: LEXX) Tech for Improving Pharmaceutical Drugs
March 07, 2022
Via
Investor Brand Network
Lexaria's DehydraTECH(TM) Demonstrates Faster Delivery Of Sildenafil
↗
March 04, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience Corp. (NASDAQ: LEXX)...
Via
Benzinga
Lexaria’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates Faster Delivery of Sildenafil
March 04, 2022
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates Faster, Higher Overall Delivery of Sildenafil into Bloodstream
March 03, 2022
Via
CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates Faster, Higher Overall Delivery of Sildenafil into Bloodstream
March 03, 2022
Via
Investor Brand Network
Lexaria Bioscience Optimistic Of Positive Study Results
↗
February 28, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice....
Via
Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Optimistic of Positive Study Results
February 28, 2022
Via
Investor Brand Network
As It Targets Multiple Large Market Opportunities, Lexaria Bioscience Corp. (NASDAQ: LEXX) Is Leveraging Elaborate Studies to Progressively Remove Risks Associated with Commercialization, Regulation
February 28, 2022
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Optimistic of Positive Study Results, Eyes ‘Most Exciting Year Ever’
February 25, 2022
Via
CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Optimistic of Positive Study Results, Eyes ‘Most Exciting Year Ever’
February 25, 2022
Via
Investor Brand Network
Lexaria Optimistic About Expanded DehydraTECH Investigations
↗
February 23, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria just announced ground-breaking...
Via
Benzinga
Lexaria (NASDAQ: LEXX) Optimistic About Expanded DehydraTECH Investigations
February 23, 2022
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Optimistic About its Expanded DehydraTECH Investigations; Plans for More Studies in 2022
February 23, 2022
Via
Investor Brand Network
Lexaria World Leader Through DehydraTECH(TM) – Its Pioneering Drug Delivery Tech
↗
February 22, 2022
Photo by Shelby Ireland on Unsplash
Via
Benzinga
Lexaria (NASDAQ: LEXX) World Leader Through DehydraTECH(TM) – Its Pioneering Drug Delivery Tech
February 22, 2022
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Is World Leader Through DehydraTECH(TM) – Its Pioneering Drug Delivery Technology
February 18, 2022
Via
CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Is World Leader Through DehydraTECH(TM) – Its Pioneering Drug Delivery Technology
February 18, 2022
Via
Investor Brand Network
Following Sildenafil Study, Lexaria Announces Plans For More Studies In 2022
↗
February 17, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria’s animal study could be...
Via
Benzinga
Following Sildenafil Study, Lexaria (NASDAQ: LEXX) Announces Plans for More Studies in 2022
February 17, 2022
Via
Investor Brand Network
< Previous
1
2
...
21
22
23
24
25
26
27
28
29
...
32
33
Next >
